Dr Rosemary Gillespie appointed as Chief Executive of Terrence Higgins Trust.

by THT | 3rd January 2014

HIV and sexual health charity Terrence Higgins Trust is pleased to announce the appointment of Dr Rosemary Gillespie as its new Chief Executive.

Dr Gillespie joins the charity from the role of Chief Executive of international HIV awareness charity AVERT. Her previous roles have included Deputy Chief Executive and Director of Policy and Research for Breast Cancer Care, and Chief Executive of the Roy Castle Lung Cancer Foundation.

Dr Gillespie said: 'I am delighted to have been appointed as Chief Executive of this outstanding and iconic charity. I look forward to working with staff and volunteers in the next phase of development, growth and innovation, as we face new challenges in the fields of HIV and sexual health, and continuing attempts to eradicate prejudice and discrimination.'

Professor Chris Bones, Chair of Trustees at Terrence Higgins Trust, said: “The Trustees are delighted to have secured Dr Gillespie as the new CEO. She brings a remarkable combination of clinical practice, health management and charity leadership at a critical time for our development. No organisation can stay still in the current economic climate and Dr Gillespie's track record of successful change and innovation across a number of sectors will help us meet the challenges ahead in both HIV and the wider area of sexual health.”

The recruitment process was provided by executive search firm The Talent Business, working on a pro bono basis. Kate Harrison, Partner at The Talent Business, said: 'The Talent Business is used to leading ‘C Suite’ talent searches on a daily basis, but it has been a particular pleasure to partner Terrence Higgins Trust in the search for a new CEO. From the outset I believe we had real alignment in what was needed from the future leader of the charity, and both the process and outcome were designed innovatively as a result. I believe the organisation deserves an inspirational leader to help it grow to the next level, and this appointment should help secure a bright future from a bright past.'

Dr Gillespie will begin her role as Chief Executive on Tuesday 1st April. Paul Ward will remain in post as Acting Chief Executive until March.